Hydroxychloroquine-functionalized ionizable lipids mitigate inflammatory responses in mRNA therapeutics

Kepan Chen, Xuechun Li, Shuo Feng, Ye Li, Ting Jiang, Yan Liu, Na Guo, Xiaoling Zeng, Hongwei Yao, Min Qiu, Jing Lü, Jinzhong Lin

TL;DR

Researchers have developed novel lipid nanoparticles (LNPs) by incorporating hydroxychloroquine (HCQ) into their structure. These HCQ-functionalized LNPs (HL-LNPs) effectively deliver mRNA while significantly reducing the inflammatory responses typically associated with ionizable lipids, paving the way for safer and more versatile mRNA therapeutics.

What Problem Does This Paper Address?

The success of mRNA therapeutics, particularly vaccines, has been a game-changer. However, a major hurdle for their broader application, especially in therapies requiring repeated dosing, is the inflammatory response triggered by the ionizable lipids used in the delivery vehicles (LNPs). These lipids, essential for packaging and delivering mRNA, can activate the immune system, leading to undesirable side effects and potentially compromising therapeutic efficacy. This paper tackles the challenge of mitigating these inflammatory side effects without sacrificing the crucial mRNA delivery capabilities of LNPs.

Methods

The researchers designed and synthesized a new class of ionizable lipids by functionalizing hydroxychloroquine (HCQ) with lipid tails. They explored different generations of these HCQ-derived lipids (HLs) and formulated them into LNPs. Key techniques and analyses included:

  • Lipid Synthesis and Characterization: Esterification reactions were used to create the HLs, followed by purification and structural confirmation using NMR and MS.
  • LNP Formulation and Characterization: LNPs were prepared using a microfluidic mixing method. Their particle size, polydispersity index (PDI), and encapsulation efficiency were assessed.
  • In Vitro Studies: THP1-Dual cells were used to evaluate the suppression of innate immune signaling pathways (NF-κB and IRF) induced by nucleic acids like poly(I:C).
  • In Vivo Studies:
    • mRNA Delivery Efficiency: Bioluminescence imaging was used to track mRNA expression in mice after intravenous and intramuscular administration.
  • Repeated Dosing: Mice received multiple doses of mRNA-loaded LNPs to assess sustained expression and immune response.
  • Immunogenicity: An mRNA vaccine against Varicella-Zoster Virus (VZV) was developed and tested for humoral and cellular immune responses.
  • Gene Editing: CRISPR-Cas9 mRNA was delivered via HL-LNPs to target the PCSK9 gene in mice to assess cholesterol-lowering effects.
  • Physicochemical Stability: Freeze-thaw cycles and cryo-electron microscopy (cryo-EM) were used to evaluate LNP stability.
  • Molecular Dynamics (MD) Simulations: These were employed to understand the interactions between HL lipids, mRNA, and their distribution within the LNP.

Datasets

Not explicitly discussed as datasets in the paper. The experiments utilized:

  • In vitro cell cultures: THP1-Dual cells.
  • Animal models: BALB/c mice and C57BL/6J mice.
  • mRNA constructs: Firefly luciferase (FLuc) mRNA, VZV gE mRNA, and Cas9 mRNA.
  • Nucleic acids: Poly(I:C) and sgPCSK9.

Key Insights and Ideas

  • HCQ as a Functional Component: Hydroxychloroquine, known for its anti-inflammatory properties, can be effectively integrated into ionizable lipids to create LNPs that suppress inflammatory responses. This is a novel approach to directly address LNP-induced inflammation.
  • Structural Basis for Reduced Inflammation: The HCQ functionalization leads to distinct LNP structures with enhanced stability and altered lipid distribution, with HL lipids showing a greater tendency to localize within the LNP core. This structural difference is key to their reduced inflammatory potential.
  • Tailoring LNP Properties: The choice of lipid tail significantly influences encapsulation efficiency and delivery performance, highlighting the importance of rational design in optimizing HL-LNPs.
  • Sustained mRNA Expression: HL-LNPs not only reduce inflammation but also enable sustained mRNA expression over multiple doses, addressing a critical limitation of current LNP formulations.
  • Broad Applicability: The demonstrated efficacy in vaccine models and gene editing applications suggests HL-LNPs are versatile and can be applied to a wide range of nucleic acid-based therapies where minimizing inflammation is crucial.

Key Results

  • Reduced Pro-inflammatory Cytokines: HL-LNPs significantly reduced the release of key pro-inflammatory cytokines (TNF-α, IFN-γ, IL-6, MCP-1) compared to conventional SM-102 LNPs in both in vitro and in vivo settings.
  • Efficient mRNA Delivery: HL-LNPs maintained comparable or even improved mRNA expression levels compared to SM-102 LNPs, particularly in repeated dosing scenarios.
  • Enhanced Stability: HL-LNPs exhibited greater stability against freeze-thaw cycles compared to SM-102 LNPs.
  • Robust Immune Response (Vaccine Model): HL-gE vaccines induced comparable humoral immune responses and strong Th1-biased cellular immunity to SM-102-gE vaccines, without the excessive cytokine release.
  • Effective Gene Editing: HL-6 LNPs delivered Cas9 mRNA for PCSK9 gene editing, achieving significant cholesterol reduction comparable to SM-102 LNPs.
  • Improved Survival: In a poly(I:C) toxicity challenge, HL-6 LNPs provided 100% survival, while SM-102 LNPs showed complete mortality.

Limitations and Future Work

  • Tail Structure Optimization: The paper suggests that further optimization of the lipid tail structure could enhance delivery performance and encapsulation efficiency of HL-lipids.
  • Broader Applications: Future research will focus on the application of HL-LNPs for delivering DNA and self-amplifying RNA (saRNA), which are often associated with strong inflammatory responses.
  • Specific Mechanisms: While the study highlights the structural differences and HCQ's role, further detailed mechanistic investigations into the precise interactions and pathways involved in immune suppression could be beneficial.
  • HL-5 Performance: The study noted that HL-5, a conjugate of HCQ and SM-102, was still inflammatory, suggesting that the overall lipid architecture, not just the presence of HCQ, is critical for mitigating inflammation. This implies that simply adding HCQ to existing inflammatory lipids may not be sufficient.

Summary updated

Abstract

Abstract Lipid nanoparticle (LNP)-based mRNA therapeutics, highlighted by the success of SARS-CoV-2 vaccines, face challenges due to inflammation caused by ionizable lipids. These ionizable lipids can activate the immune system, particularly when co-delivered with nucleic acids, leading to undesirable inflammatory responses. We introduce a novel class of anti-inflammatory ionizable lipids functionalized with hydroxychloroquine (HCQ), which suppresses both lipid-induced and nucleic acid-induced immune activation. These HCQ-functionalized LNPs (HL LNPs) exhibit reduced proinflammatory responses while maintaining efficient mRNA delivery. Structural and physicochemical analyses revealed that HCQ-functionalization results in a distinct particle structure with significantly improved stability. The efficacy of HL LNPs was demonstrated across various therapeutic contexts, including a prophylactic vaccination model against varicella-zoster virus (VZV) and CRISPR-Cas9 gene editing targeting PCSK9. Notably, HL LNPs showed robust mRNA expression after repeated administration, addressing concerns of inflammation and ensuring sustained therapeutic effects. These findings highlight the potential of HCQ-functionalized LNPs in expanding the safe use of mRNA therapeutics, particularly for applications requiring repeated dosing and in scenarios where inflammation-induced side effects must be minimized.
BibTeX
@article{chen2025hydroxychloroquine,
  author = {Kepan Chen and Xuechun Li and Shuo Feng and Ye Li and Ting Jiang and Yan Liu and Na Guo and Xiaoling Zeng and Hongwei Yao and Min Qiu and Jing Lü and Jinzhong Lin},
  title = {{Hydroxychloroquine-functionalized ionizable lipids mitigate inflammatory responses in mRNA therapeutics}},
  journal = {Journal of Controlled Release},
  year = {2025},
  doi = {10.1016/j.jconrel.2025.114267},
}
Figure